S. W. Ong

Antibody response of heterologous vs homologous mRNA vaccine boosters against the SARS-CoV-2 Omicron variant: interim results from the PRIBIVAC study, A Randomized Clinical Trial

L. Rénia, L. Ng, E. Ren, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Efficient recall of SARS‐CoV‐2 variant‐reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boosters

M. Tay, L. Rénia, P. MacAry, 2022, Journal of medical virology.

SARS-CoV-2 RNA and nucleocapsid antigen are blood biomarkers associated with severe disease outcomes that improve in response to remdesivir.

Michael R. Wierzbicki, S. Zakynthinos, F. Sutterwala, 2024, The Journal of infectious diseases.